Alzheimer’s Disease

  • G. B. Frisoni
Part of the Topics in Neuroscience book series (TOPNEURO)


Clinical trials of Alzheimer’s disease (AD) traditionally use rating scales, such as neuropsychological tests, and disability scales as outcome measures. However, their intrinsic measurement variability, the slow disease progression, and the low efficacy of the drugs developed so far have led to trial designs with hundreds of subjects per treatment arm. The development of imaging markers with proven sensitivity to disease progression has recently paved the way for their use as outcome measures in clinical trials. The use of imaging measures has the double advantage of decreasing the number of subjects per treatment arm whilst also providing a direct measure of the degree of disease modification induced by the “active” molecules. A number of magnetic resonance (MR)-based markers have been developed for clinical trials of AD, all of which have their own strengths and weaknesses. Here, the most often used techniques, which could easily be exported to the study of neurodegeneration in clinical trials of multiple sclerosis, are reviewed.


Mild Cognitive Impairment Hippocampal Volume Gray Matter Loss Antibody Responder Pocampal Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Laakso MP, Partanen K, Riekkinen P et al (1996) Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 46:678–681PubMedGoogle Scholar
  2. 2.
    Laakso MP, Soininen H, Partanen K et al (1998) MRI of the hippocampus in Alzheimer’s disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging 19:23–31PubMedCrossRefGoogle Scholar
  3. 3.
    Jack CR, Jr, Petersen RC, Xu YC et al (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397–1403PubMedGoogle Scholar
  4. 4.
    Jack CR, Jr, Petersen RC, Xu Y et al (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489PubMedGoogle Scholar
  5. 5.
    Fox NC, Freeborough PA (1997) Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer’s disease. J Magn Reson Imaging 7:1069–1075PubMedCrossRefGoogle Scholar
  6. 6.
    Ashburner J, Csernansky JG, Davatzikos C et al (2003) Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol 2:79–88PubMedCrossRefGoogle Scholar
  7. 7.
    Ashburner J, Friston KJ (2000) Voxel-based morphometry: the methods. Neuroimage 14:805–821CrossRefGoogle Scholar
  8. 8.
    Thompson PM, Mega MS, Toga AW (2000) Disease-specific brain atlases. In: Toga AW, Mazziotta JC (eds) Brain mapping: the disorders. Academic Press, San Diego, CA, pp 131–177Google Scholar
  9. 9.
    Freeborough PA, Fox NC, Kitney RI (1997) Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 53:15–25PubMedCrossRefGoogle Scholar
  10. 10.
    Chetelat G, Landeau B, Eustache F et al (2005) Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 27:934–946PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson PM, Toga AW (1996) A surface-based technique for warping 3-dimensional images of the brain. IEEE Trans Med Imaging 15:1–16CrossRefGoogle Scholar
  12. 12.
    Thompson PM, Hayashi KM, de Zubicaray G et al (2003) Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 23:994–1005PubMedGoogle Scholar
  13. 13.
    Vidal CN, Rapoport JL, Hayashi KM et al (2006) Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Arch Gen Psychiat 63:25–34PubMedCrossRefGoogle Scholar
  14. 14.
    Smith SM, De Stefano N, Jenkinson M, Matthews PM (2001) Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 25:466–475PubMedCrossRefGoogle Scholar
  15. 15.
    Resnick SM, Goldszal AF, Davatzikos C et al (2000) One-year age changes in MRI brain volumes in older adults. Cereb Cortex 10:464–472PubMedCrossRefGoogle Scholar
  16. 16.
    Davatzikos C, Resnick SM (1998) Sex differences in anatomic measures of interhemispheric connectivity: correlations with cognition in women but not in men. Cereb Cortex 8:635–640PubMedCrossRefGoogle Scholar
  17. 17.
    Fox NC, Black RS, Gilman S et al (2005) Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64:1563–1572PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • G. B. Frisoni
    • 1
  1. 1.LENITEM — Laboratory of Epidemiology Neuroimaging & Telemedicine IRCCS San Giovanni di DioThe National Center for Research and Care of Alzheimer’s DiseaseBresciaItaly

Personalised recommendations